Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Growth (Status and Outlook) 2023-2029

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Growth (Status and Outlook) 2023-2029

The global Circulating Tumor Cells (CTC) Liquid Biopsy market size is projected to grow from US$ 1071.2 million in 2022 to US$ 2715.5 million in 2029; it is expected to grow at a CAGR of 14.2% from 2023 to 2029.

North America dominates global circulating tumor cells (CTC) liquid biopsy market. This is majorly due to the growing adoption of the liquid biopsy in the North American region for diagnosis of cancer. There are rapidly growing cases of cancer in US which has contributed in the dominance of North America in the global liquid biopsy market.

LPI (LP Information)' newest research report, the “Circulating Tumor Cells (CTC) Liquid Biopsy Industry Forecast” looks at past sales and reviews total world Circulating Tumor Cells (CTC) Liquid Biopsy sales in 2022, providing a comprehensive analysis by region and market sector of projected Circulating Tumor Cells (CTC) Liquid Biopsy sales for 2023 through 2029. With Circulating Tumor Cells (CTC) Liquid Biopsy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Circulating Tumor Cells (CTC) Liquid Biopsy industry.

This Insight Report provides a comprehensive analysis of the global Circulating Tumor Cells (CTC) Liquid Biopsy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Circulating Tumor Cells (CTC) Liquid Biopsy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Circulating Tumor Cells (CTC) Liquid Biopsy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Circulating Tumor Cells (CTC) Liquid Biopsy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Circulating Tumor Cells (CTC) Liquid Biopsy.

This report presents a comprehensive overview, market shares, and growth opportunities of Circulating Tumor Cells (CTC) Liquid Biopsy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Kits & Reagents
Blood Collection Tubes
Devices

Segmentation by application
Research & Academic Institutes
Hospitals
Physician Laboratories
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
QIAGEN
Bio-Techne
Precision Medical
Aviva Systems Biological
Biocept
Fluxion Biosciences
Greiner Bio-One International GmbH
Ikonisys
Miltenyi Biotec
IVDiagnostics
BioFluidica
Canopus Medical
Biolidics
Creativ MicroTech
LungLife AI
Epic Sciences
Rarecells Diagnostics
ScreenCell
Menarini Silicon Biosystems

Please note: The report will take approximately 2 business days to prepare and deliver.